Plaque Psoriasis

Findings suggest pediatric patients with guttate or inverse psoriasis may warrant evaluation for pharyngeal or anogenital bacterial infections.

Overall, older treatment strategies such as methotrexate and phototherapy still led the way for cost-effectiveness.

This FDA news recap highlights some of the most notable approvals and actions by the organization in dermatology during Q2 2025.

In our recap for Q2 in dermatology, we spotlight clinical trial findings, recent updates, and advancements in different disease states.

In the BE BRIGHT trial presented at SDPA 2025, patients receiving continuous bimekizumab therapy maintained high PASI 90 and PASI 100 response rates over 5 years.

At SDPA 2025, Gordon presented on the future of dermatology, discussing current drugs being evaluated for atopic dermatitis, psoriasis, and hidradenitis suppurativa.

More than 60% of patients with psoriasis achieved PASI 100 at week 16 with bimekizumab and maintained skin clearance up to 4 Years.

This analysis highlights the risk of superficial fungal infections among patients with moderate-to-severe psoriasis given biologics such as IL-17 inhibitors.

This analysis highlights the observed risk of developing psoriasis when using dupilumab to treat atopic dermatitis.

Recent research comparing the two diseases against a sample of the general population has indicated a substantially higher mortality risk and rate in GPP than in plaque psoriasis.

Study findings highlight a heightened risk of MetS in patients with psoriasis, especially those with more severe disease based on PASI scores.

Research has indicated a suggestive association between predicted psoriasis and uterine corpus cancer in women and prostate cancer in men.

This approval of roflumilast foam as a once-daily topical treatment for psoriasis of the scalp and body followed the phase 3 ARRECTOR study findings.

AC-201 at 25, 50, and 100 mg doses show promising phase 2 results, significantly reducing psoriasis severity.

This interview with Jennifer Soung, MD, highlights the implications of recent phase 3 findings on roflumilast foam 0.3% (Zoryve) for psoriasis of the scalp and body.

In this analysis, investigators looked at the extent to which psoriasis severity correlates with patients’ risk of developing sleep disorders.

This interview with Andrew Alexis, MD, MPH, highlights the unique clinical challenges of high-impact areas of psoriasis such as the scalp and hands.

These data from the ICONIC-TOTAL trial program highlight icotrokinra’s use as a selective IL-23 inhibitor and its effectiveness in skin clearance for psoriasis.

These findings support the conclusion that switching between adalimumab biosimilars largely maintains efficacy for patients with psoriasis.

These phase 3 findings from the ARRECTOR trial, published in JAMA, demonstrate rapid and significant relief from plaque psoriasis with roflumilast foam use.

This analysis highlighted the cardiovascular safety of systemic psoriasis drugs using a prospective cohort trial design.

These post-hoc analysis findings align with POETYK PSO-4 regarding deucravacitinib’s effectiveness in patients with psoriasis.

This analysis suggests intake of riboflavin, also known as vitamin B2, shows an association with patients’ risk of developing psoriasis.

These results highlight the association between nail psoriasis and various factors such as male sex and smoking.